NCT06564467View on ClinicalTrials.gov

A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JMT202

PHASE1Enrolling by invitationINTERVENTIONAL

Enrollment

54

Participants

Timeline

Start Date

July 23, 2024

Primary Completion Date

January 10, 2025

Study Completion Date

July 10, 2025

Conditions

Healthy Subjects

Interventions

DRUG

JMT202

subcutaneous injection

DRUG

Placrbo

subcutaneous injection

Trial Locations (1)

Unknown

Peking University First Hospital, Beijin

All Listed Sponsors

lead

Shanghai JMT-Bio Inc.

INDUSTRY